However, this finding allows us to speculate that an adaption of the immunological system to the tumour p16 status is either still maintained even one year after tumour eradication or that there is a fundamental difference in the patient’s immunological system, perhaps conveying a susceptibility to HPV infection from the start. This evidence concerns the gene CDKN2A and neoplasm.